IP Library Granted Patent US 8,991,401
Granted Patent B2
US 8,991,401 · App. 12/935,484 · Granted Mar 31, 2015

Processes and apparatus for preventing, delaying or ameliorating one or more symptoms of presbyopia

Inventors: George J. McArdle (Naperville, IL); Jerry R. Kuszak (Chicago, IL)
Assignee: Lenticular Research Group, LLC
A61N7/02A61F9/00825A61F9/0079A61F9/008A61F9/00817A61F2009/00844A61F2009/0087A61F2009/00874A61F2009/00895A61F2009/00897A61F2250/0095
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,991,401
App. No.
12/935,484
Granted
Mar 31, 2015
Kind
B2
Abstract

The present invention generally relates to an apparatus and processes for preventing or delaying presbyopia. More particularly, the present invention relates to processes and apparatus for ablating epithelial cells in the germinative zone or the pregerminative zone of the crystalline lens of the eye so that onset or progression of presbyopia or one or more symptoms is delayed or prevented. The present invention also relates to processes and apparatus for promoting formation of suture lines in the crystalline lens of the eye so that onset or progression of presbyopia or one or more symptoms is delayed or prevented. The present invention also relates to processes and apparatus for creating disruptions in the vitreous humor of the eye.

Claims (20)

1. A process for preventing, delaying or ameliorating one or more symptoms of presbyopia in a patient, the process comprising promoting one or more of reproduction of epithelial cells, formation of fiber cells, or formation of sutures, in a crystalline lens of at least one eye of the patient,

wherein the process comprises one or more of:

identifying and/or protecting mitotically active epithelial cells, and ablating mitotically inactive epithelial cells in the germinative zone or the pregerminative zone of the crystalline lens;

creating one or more disruptions in the aqueous humor or the vitreous humor or both of the eye; or

altering a balance of growth factors in the anterior humor or vitreous humor or both, in one or both eyes of the patient.

2. The process according to claim 1 , wherein the process comprises promoting mitosis of epithelial cells in the crystalline lens.

3. The process according to claim 1 , wherein the process comprises promoting cytokinesis of epithelial cells in the crystalline lens.

4. The process according to claim 1 , wherein the process comprises promoting formation of fiber cells in the crystalline lens.

5. The process according to claim 4 , wherein the process comprises promoting the differentiation of epithelial cells into fiber cells.

6. The process according to claim 1 , wherein the crystalline lens comprises a number of fiber cells, and the process comprises increasing the number of fiber cells in the crystalline lens.

7. The process according to claim 1 , wherein the process comprises ablating epithelial cells in the germinative zone or the pregerminative zone of the crystalline lens, wherein a sufficient number or arrangement of ablation points are made so as to increase the number of fiber cells in the crystalline lens.

8. The process according to claim 1 , further comprising the step of identifying mitotically active epithelial cells, and ablating mitotically inactive epithelial cells.

9. The process of according to claim 1 , further comprising the step of protecting mitotically active epithelial cells from ablation, and ablating mitotically inactive epithelial cells.

10. The process of according to claim 1 , wherein the process comprises promoting formation of new branches from existing sutures in the crystalline lens.

11. The process of claim 10 , wherein the process comprises creating one or more disruptions in the aqueous humor or the vitreous humor or both of the eye.

12. The process of claim 11 , wherein the patient's eye has a corneal-scleral junction and vitreous humor located behind the crystalline lens, and the process comprises inserting a needle at a corneal-scleral junction into the vitreous humor.

13. The process of claim 12 , wherein the process comprises creating perforations symmetrically around the crystalline lens.

14. The process according to claim 13 , wherein the process comprises increasing flow of growth factors into the crystalline lens without perforating the lens capsule.

15. The process according to claim 1 , wherein the process comprises ablating epithelial cells in the crystalline lens using ultrasonic or radiofrequency energy.

16. The process according to claim 1 , wherein the process comprises ablating epithelial cells in the crystalline lens using high intensity focused ultrasound.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2012
From: MCARDLE, GEORGE R.; KUSZAK, JERRY R.
To: LENTICULAR RESEARCH GROUP, LLC
Reel/Frame 028297/0416 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2012
From: MCARDLE, GEORGE J.; KUSZAK, JERRY R.
To: LENTICULAR RESEARCH GROUP, LLC
Reel/Frame 028297/0795 →
Continuity (3)
Provisional Application 61048536 · Apr 28, 2008
Provisional Application 61072621 · Mar 31, 2008
Related Publication 20110160622A1 · Jun 30, 2011